Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Long-term follow-up of venetoclax monotherapy in previously treated Waldenström macroglobulinemia shows median PFS 36 mos, median treatment-free survival 43 mos, no BCL2 G101V mutations in 52 CD19-selected samples.”
Title: Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia
Authors: Jorge J. Castillo, Alberto Guijosa, John N. Allan, Tanya Siddiqi, Ranjana H Advani, Catherine Flynn, Kirsten E. Meid, Nina Budano, Julia Nguyen, Andres Ramirez-Gamero, Nicholas Tsakmaklis, Zachary R Hunter, Christopher J Patterson, Steven P. Treon, Shayna Sarosiek
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski in OncoDaily.
